Technical Analysis for INCY - Incyte Corporation

Grade Last Price % Change Price Change
grade C 79.23 0.70% 0.55
INCY closed up 2.41 percent on Tuesday, May 21, 2019, on 84 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Up
See historical INCY trend table...

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.70%
Narrow Range Bar Range Contraction 3.12%
NR7 Range Contraction 3.12%
20 DMA Resistance Bearish 2.05%
MACD Bearish Signal Line Cross Bearish 4.26%
Narrow Range Bar Range Contraction 4.10%
NR7 Range Contraction 4.10%
Fell Below 20 DMA Bearish 4.59%
MACD Bearish Centerline Cross Bearish 4.59%
Down 3 Days in a Row Weakness 4.59%

Older signals for INCY ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary small molecule drugs for oncology and inflammation. The company markets JAKAFI, an oral janus associated kinase (JAK) inhibitor for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF. Its product pipe line includes ruxolitinib, a JAK inhibitor, which is in Phase III clinical trial for polycythemia vera; Phase II trial for essential thrombocythemia; Phase II trial for pancreatic cancer; Phase I/II trial to treat solid tumors/other hematologic malignancies, as well as baricitinib, a JAK inhibitor, which is Phase III trial for rheumatoid srthritis, Phase IIb trial for psoriasis, and Phase II trial for diabetic nephropathy. The company's products in pipeline also comprise INCB28060 and INCB24360, which are Phase II clinical trial products for the treatment of solid tumors. It has a collaborative research and license agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; and Pfizer Inc. The company was founded in 1991 and is headquartered in Wilmington, Delaware.
Chemistry Biopharmaceutical Chemical Compounds Organic Compounds Solid Tumors Inflammation Psoriasis Pancreatic Cancer Diabetic Nephropathy Janus Kinase Inhibitor Myelofibrosis Clinical Trial Products Nitriles Sulfonamides
Is INCY a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 88.83
52 Week Low 57.0
Average Volume 1,282,722
200-Day Moving Average 73.2124
50-Day Moving Average 81.1325
20-Day Moving Average 78.41
10-Day Moving Average 78.375
Average True Range 2.4998
ADX 20.8
+DI 23.4055
-DI 23.1297
Chandelier Exit (Long, 3 ATRs ) 77.6606
Chandelier Exit (Short, 3 ATRs ) 79.8594
Upper Bollinger Band 85.239
Lower Bollinger Band 71.581
Percent B (%b) 0.52
BandWidth 17.418697
MACD Line -0.73
MACD Signal Line -0.6598
MACD Histogram -0.0702
Fundamentals Value
Market Cap 16.19 Billion
Num Shares 206 Million
EPS -0.79
Price-to-Earnings (P/E) Ratio -99.59
Price-to-Sales 18.19
Price-to-Book 23.14
PEG Ratio -1.27
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 81.66
Resistance 3 (R3) 81.38 80.11 81.16
Resistance 2 (R2) 80.11 79.35 80.25 81.00
Resistance 1 (R1) 79.39 78.88 79.75 79.67 80.83
Pivot Point 78.12 78.12 78.30 78.26 78.12
Support 1 (S1) 77.41 77.36 77.77 77.69 76.53
Support 2 (S2) 76.14 76.89 76.28 76.36
Support 3 (S3) 75.42 76.14 76.20
Support 4 (S4) 75.70